Hospital based interventional radiologist located in New London, CT. with special interest in event driven investing and biotechnology companies with breakthrough therapies. Sheldon Robbins, M.D. Lawrence and Memorial Hospital Dept. of Radiology 365 Montauk Ave. New London, CT 06320
I enjoy spending time day trading and analyzing the market. I’m always looking for a good swing or day trade, but mostly I’m focused on finding stocks that will hit big and up-list from the OTC to the big boards. Basically, almost all of my portfolio is traded daily, especially considering I tend to look over multiple market segments for trades instead of spending all my time on one section. I’ve been analyzing and trading stocks for over 9 years now, and I have a strong understanding of trends, as well as the knowledge to make smart trades.
I am an IT consultant by profession. I have strong interest in the Market and have been investing in US markets since 1995. My experience has taught me a lot over the years. I have two fold investment strategy one to invest in good stocks at good value/technical entry points and also invest some capital (play money) on quick trades days or weeks depending on technical setups. I primarily use levered ETF's to do follow my swing trade system. I am not a good writer so I only make small comments on others blogs.
My academic background is in Engineering and management.
Besides one basic accounting course at university my investment knowledge is self-taught.
Reading books, SEC filings, annual reports, analyst reports, blog posts, MOOCs, message boards and listening to select podcasts and conference calls has helped me enormously to evolve as an investor.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
bio-seeker...of the next biotech breakthrough. Emerging small cap biotech, cancer immunotherapy, PD-1, CD47, RNAi, CAR-T, KIR/NK.
Investing decisions based on information derived from credible sources...clinical trial data, research papers and independent analysis by those who are qualified to analyze... always skeptical of sell side analysis. Never invest based on a single SA article. Always consider the bio of SA authors... 95% can be ignored altogether based on lack of expertise.
40 year career of executive leadership in IT with specialization in business development and financial analysis. I've led the formation and development of 5 technology-based business and have experienced the success and challenges that serial entrepreneurship brings. As an life-long investor, I've learned hard-taught lessons on the differences between speculation, trading, and investing. Later in life, I became a more serious student of investment and have advanced credentials in financial planning. Now, while I enjoy 'retirement' and remain active in a couple of very promising business development projects, I spend a lot of every day with the markets and enjoy the best investment performance of my life! Wishing you all the very best...
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Over 20 years experience in various financial roles. Positions included Financial Consultant with A.G. Edwards and Sons, Hedge Fund Manager for the Abacus Small Cap Growth Fund. More recently, full time focus is on investing/trading undervalued companies within strong secular industries.
I am a physicist performing systems engineering research on real-world data fusion problems. My PhD explored chaos, complex and nonlinear systems, and force networks in multiphase fluid dynamics using a bed of flowing sand.
Currently, my academic interests employ optimal estimation theory to combine multiple biased, observations of dynamic systems.
I am an individual investor in a quest to minimize portfolio rotation.
I am agnostic in terms of growth vs value, but lacking the time, the resources and (most importantly) the brains, I tend to look more among the latter set of opportunities.
I am professionally versed in the European upstream O&G arena, but skeptic on its future (and optimist about the clean-tech momentum of California).
One could argue I should have an edge in European stocks: I am from Spain and based in the UK, but like Buffett says, it's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. So my portfolio is OW US and UW Europe.
N.B. If some of my comments are overly cynic, don't be offended, just an invitation to look after your $ more carefully.
Ph.D in the Faculty of Life Sciences, Bar Ilan University, Israel
Post Doctorate, Weizmann Institute of Science, Israel
Program Manager at Peerion ltd.
publisher of 14 research articles in professional journals.
Junior Staff, Instructor in Academic Courses.
studies in Economics, Israel.
Independent trader and investor over 6 years.
2 years of managing professional investors bio forum in Israel.
2 years at Aradial technologies in. Aradial Converged Billing Software - ARCB - Convergent Billing
I'm a value investor focused on buying companies trading below the intrinsic value.
I've a back ground in engineering & finance. I'm also a Chartered Financial Analyst. I did my MBA from Emory University's Goizueta School of Business